Natera, Inc. (NTRA)
Market Cap | 12.61B |
Revenue (ttm) | 1.21B |
Net Income (ttm) | -365.46M |
Shares Out | 122.80M |
EPS (ttm) | -3.12 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 920,132 |
Open | 102.18 |
Previous Close | 102.15 |
Day's Range | 101.16 - 104.58 |
52-Week Range | 36.90 - 117.23 |
Beta | 1.48 |
Analysts | Strong Buy |
Price Target | 103.27 (+0.58%) |
Earnings Date | Aug 5, 2024 |
About NTRA
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplanta... [Read more]
Financial Performance
In 2023, Natera's revenue was $1.08 billion, an increase of 31.99% compared to the previous year's $820.22 million. Losses were -$434.80 million, -20.63% less than in 2022.
Financial StatementsAnalyst Forecast
According to 16 analysts, the average rating for NTRA stock is "Strong Buy." The 12-month stock price forecast is $103.27, which is an increase of 0.58% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/b/c/press19-2548080.jpg)
New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncology highlighting the utilit...
![](https://cdn.snapi.dev/images/v1/x/r/conf17-2508212.jpg)
Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that its latest research and data on prenatal and reproductiv...
![](https://cdn.snapi.dev/images/v1/y/q/press4-2500969.jpg)
Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced a new gastroesophageal cancer trial, DECIPHER, that will util...
![](https://cdn.snapi.dev/images/v1/a/5/press19-2481587.jpg)
Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of Prospera Heart™ with Donor Quantity Score (DQS)...
Final Trades: Amazon, Natera and KKR & Co.
The Investment Committee gives you their top stocks to watch for the second half.
![](https://cdn.snapi.dev/images/v1/x/m/conf11-2458789.jpg)
Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will present at the Goldman Sachs 45th Annual Global Healthca...
![](https://cdn.snapi.dev/images/v1/k/9/press2-2453509.jpg)
Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that the company will present new data on its Prospera donor-...
![](https://cdn.snapi.dev/images/v1/y/r/conf17-2446371.jpg)
Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that members of Natera's management will present at the 2024 Leerink ...
![](https://cdn.snapi.dev/images/v1/z/n/press14-2445182.jpg)
Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that the company, along with its collaborators, will present new data...
![](https://cdn.snapi.dev/images/v1/l/p/press5-2422606.jpg)
Natera Reports First Quarter 2024 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today reported its financial results for the first quarter ended March 31, 2024. Rece...
![](https://cdn.snapi.dev/images/v1/z/t/press17-2408900.jpg)
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced a new publication in JCO Precision Oncology reporting on the ability ...
![](https://cdn.snapi.dev/images/v1/3/d/conf10-2404242.jpg)
Natera to Report its First Quarter 2024 Results on May 9
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that it will release results for its first quarter ended March 31, 20...
![](https://cdn.snapi.dev/images/v1/s/g/press6-2402254.jpg)
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced the launch of a new cfDNA-based fetal RhD test. This comes at...
![](https://cdn.snapi.dev/images/v1/x/h/press7-2382889.jpg)
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) and genetic testing, today announced that it has passed a significant milestone with the publicati...
![](https://cdn.snapi.dev/images/v1/u/j/press16-2367026.jpg)
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced a new publication from the ProActive study in Transplantation supporting ...
![](https://cdn.snapi.dev/images/v1/f/y/press2-2360806.jpg)
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced the publication of two major studies, DTRT-2 and Trifecta-Heart, showcasi...
![](https://cdn.snapi.dev/images/v1/e/o/press7-2358261.jpg)
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced an analysis from the IMvigor011 study that was presented at the European Associat...
![](https://cdn.snapi.dev/images/v1/o/j/press18-2350751.jpg)
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, and the Alliance for Clinical Trials in Oncology, which is part of the National Clinical Trials N...
![](https://cdn.snapi.dev/images/v1/l/p/press14-2328443.jpg)
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a collaboration with the Fédération Francophone de Cancérologie Digestive and CHU...
![](https://cdn.snapi.dev/images/v1/b/t/press10-2324162.jpg)
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, commented today on the 2024 Clinical Practice Guideline for the Evaluation and Management of Chro...
![](https://cdn.snapi.dev/images/v1/j/g/conf14-2319777.jpg)
Natera to Present New Data at the 2024 SGO Annual Meeting on Women's Cancer, Following Recent Medicare Coverage Decisions in Ovarian and Breast Cancers
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced new data being presented on its personalized and tumor-informed molecular residua...
![](https://cdn.snapi.dev/images/v1/g/s/press10-2312979.jpg)
Natera Announces Commercial Coverage for Prospera™ Kidney and Prospera Heart™ from a Top BCBS Plan
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has received commercial insurance coverage for its Prospera Heart...
![](https://cdn.snapi.dev/images/v1/y/s/conf20-2300993.jpg)
Natera to Participate in March Investor Conferences
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will participate in the following investor conferences in March. Raymond ...
![](https://cdn.snapi.dev/images/v1/h/m/press8-2299573.jpg)
Natera Reports Fourth Quarter and Full Year 2023 Financial Results
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today reported its financial results for the fourth quarter and year ended December 31, 2023. Rec...
![](https://cdn.snapi.dev/images/v1/i/1/press17-2295687.jpg)
Natera Announces Next Phase of CareDx Patent Infringement Litigation Seeking Royalty For All Ongoing And Future AlloSure Tests
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced the next phase of proceedings in its patent infringement litigation against CareD...